Seeing Is Believing

Currently out of the existing stock ratings of Matthew Taylor, 156 are a BUY (61.66%), 77 are a HOLD (30.43%), 20 are a SELL (7.91%).
Analyst Matthew Taylor, currently employed at UBS, carries an average stock price target met ratio of 61.25% that have a potential upside of 16% achieved within 150 days. Previously, Matthew Taylor worked at JEFFERIES.
Matthew Taylor’s has documented 517 price targets and ratings displayed on 37 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BSX, Boston Scientific Corp at 24-Jun-2026.
Analyst best performing recommendations are on TNDM (TANDEM DIABETES CARE).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 11/27/2018. The price target of $36 was fulfilled within 2 days with a profit of $2.71 (8.14%) receiving and performance score of 40.7.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 06-Jun-2019
$112
$8.94 (8.67%)
$136
15 days ago
(17-Jul-2026)
15/21 (71.43%)
$11.32 (11.24%)
415
Buy Since 19-Sep-2024
$118
$14.94 (14.50%)
$115
15 days ago
(17-Jul-2026)
2/8 (25%)
$17.32 (17.20%)
143
Buy Since 18-Jul-2018
$120
$16.94 (16.44%)
$112
15 days ago
(17-Jul-2026)
10/20 (50%)
$19.32 (19.19%)
290
Buy Since 23-Oct-2018
$120
$16.94 (16.44%)
$135
15 days ago
(17-Jul-2026)
8/9 (88.89%)
$19.32 (19.19%)
339
Buy Since 02-Jun-2021
$134
$30.94 (30.02%)
$131
15 days ago
(17-Jul-2026)
9/22 (40.91%)
$33.32 (33.09%)
559
Which stock is Matthew Taylor is most bullish on?
Which stock is Matthew Taylor is most reserved on?
What Year was the first public recommendation made by Matthew Taylor?